This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Martinez-Cuadrón D, Serrano L, Gil C, Tormo M, MartÃnez-Sánchez P, Pérez-Simón J, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. e-published 19 October 2020
Wei AH, DiNardo CD. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135:85–96.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MV, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax + LDAC for newly-diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized, placebo-controlled trial. Blood. 2020;135:2137–45.
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–89.
Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leuekmia: what’s the best endpoint? Leukemia. 2016;30:521–5.
Estey E, Karp JP, Othus M, Emadi A, Gale RP. Recent drug approvals for newly-diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34:671–81.
Amrhein V, Greenland S, McShane B. Retire statistical significance. Nature. 2019;367:305–7.
Gale RP, Hochhaus A, Zhang MJ. What is the (p-) value of the P-value? Leukemia. 2016;30:1965–7.
Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia? Leukemia. 2017;31:1255–8.
Livingston E. Success of antibiotic therapy vs laparoscopic appendectomy for uncomplicated appendicitis in children; a matter of perspective. JAMA. 2020;324:594.
Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. Haematologica. 2018;103:2040–8.
Schiffer CA. An important gap in informed consent documents for oncology clinical trials: lack of quantitative data about expected treatment outcomes. JAMA Oncol. 2019;5:1399–400.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Estey, E. New treatments for acute myeloid leukemia: how much has changed?. Leukemia 35, 45–46 (2021). https://doi.org/10.1038/s41375-020-01084-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-01084-2